Supplementary Protection Certificate (SPC) Summary | |||
SPC No. | 2013/035 | ||
---|---|---|---|
Date of filing | 15/07/2013 | ||
Notification of Application Published | 14/08/2013 | ||
Status | Rejected | ||
Notification of Grant Published | |||
Date of Expiry of SPC | |||
Applicant |
NOVO NORDISK A/S Novo Alle 2880 Bagsvaerd DENMARK |
||
Patent Number | 2107069 | ||
Title of Invention | Novel insulin derivatives | ||
Date of Expiry of Patent | 21/07/2024 | ||
Product Type | Medicinal Product | ||
Product Identity | Combinatin of insulin degludec and insulin aspart in all its forms as they are protected by the basic patents | ||
Market Authorisation | Ireland | ||
Authorisation No | EU/1/12/806/001,004,005,007 and 008 | ||
Authorisation Date | 21/01/2013 | ||
Identity of Product Authorised | Ryzodeg-insulin degludec and insulin aspart | ||
Address for Service |
TOMKINS & CO. 5 Dartmouth Road Dublin 6 IRELAND |
||
Renewal Fees | |||
18/07/2013 | Request for grant a Supplementary Protection Certificate filed on 15/07/2013, numbered 2013/035. | ||
21/12/2018 | Request for grant of Supplementary Protection Certification No. 2013/035 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||
24/03/2021 | Written grounds of decision issued on 14 January 2019. |